# US 2026/0297516 A1 · Xeno-free and transgene-free reprograming of mesenchymal stem cells toward neural progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297516 A1
- Document ID: US20260297516A1
- Status: Published application
- Kind: A1
- Application number: 19/567,992
- Filed: 2026-03-16
- Published: 2026-10-01
- Earliest claimed: 2019-05-24
- Applicants: University of Central Florida Research Foundation, Inc.; Institute for Scientific Research and Technology Services (Indicasat)
- Inventors: Kiminobu SUGAYA; Luis Sebastian Alexis VALERIO
- Web page: https://patentgrep.com/patent/US20260297516A1

## CPC

- C12N 5/0623: {Stem cells}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- C12N 2500/38: Vitamins
- C12N 2500/40: Nucleotides, nucleosides or bases
- C12N 2501/06: Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/113: Acidic fibroblast growth factor (aFGF, FGF-1)
- C12N 2501/91: Heparin
- C12N 2502/088: neural stem cells
- C12N 2506/1346: from mesenchymal stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are methods and materials for transdifferentiating mesenchymal stem cells into neural progenitor cells.

## Claims

### Claim 1

Cells obtained from a method comprising (a) obtaining mesenchymal stem cells whose epigenetic status has been modified with an epigenetic modifier; and (b) contacting the mesenchymal stem cells of step (a) with extracellular vesicles obtained from neural stem cells under conditions to allow the mesenchymal stem cells to convert into neural progenitor cells.

### Claim 2 (depends on 1)

A method of treating a subject comprising administering a therapeutically effective amount of the cells of claim 1 to the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cells are autologous or allogeneic to the subject.

### Claim 4

A method of generating a population of neural progenitor cells, comprising: providing mesenchymal stem cells; and reprogramming the cells under conditions to obtain a culture of enriched neural progenitor cells with increased expression of two or more markers upregulated in neural progenitor cells.

### Claim 5 (depends on 4)

The method of claim 4, wherein the two or markers comprise SRY (sex determining region Y)-box 1 (SOX1), CD90, GFAP, SRY (sex determining region Y)-box 2 (SOX2) or paired box 6 (PAX6), or any combination thereof.

### Claim 6 (depends on 5)

Cells obtained by the method of claim 5.

### Claim 7 (depends on 6)

A method of treating a neurological deficit in a subject comprising administering a therapeutically effective amount of the cells of claim 6 to the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cells are autologous or allogenic to the subject.

### Claim 9 (depends on 7)

The method of claim 7, wherein the neurological deficit is caused by a neurodegenerative disease, a traumatic injury, a neurotoxic injury, ischemia, a developmental disorder, a disorder affecting vision, an injury or disease of the spinal cord, a demyelinating disease, an autoimmune disease, an infection, an inflammatory disease, or corporal disease, disorder, injury, trauma, malfunction, degeneration or loss.

### Claim 10

A kit comprising a first container into which a first composition comprising neural stem cell exosomes is disposed and a second container into which a second composition comprising an epigenetic modifier is disposed.

### Claim 11 (depends on 10)

The kit of claim 10, wherein the first composition comprises one or more constituents selected from the group consisting of DMEM:F12, B27 supplement, rhFGF, rhEGF, Heparin, and antibiotic.

### Claim 12 (depends on 11)

The kit of claim 11, wherein rhFGF is at about 10 ug/mL, rhEGF is at about 20 ug/mL, Heparin is at about 1000 U/mL, and antibiotic is at about 1%.

### Claim 13 (depends on 1)

The cells of claim 1, wherein the epigenetic modifier is 5-aza-2′-deoxycytidine and/or SB431542.

### Claim 14 (depends on 1)

The cells of claim 1, wherein contacting comprises (i) culturing the mesenchymal stem cells in media with neural stem cell (NSC) exosomes for 1-5 days; after step (i), (ii) refreshing the media and NSC exosomes and culturing the cells for 5-15 days; and after step (ii), (iii) providing fresh media lacking NSC exosomes and culturing the cells for at least 5-7 days, wherein the cells of step form spheres.

### Claim 15 (depends on 14)

The cells of claim 14, wherein step (ii) starts at day 4, 5, or 6 from the start of step (i); and step (iii) starts at day 14, 15, or 16 from the start of step (a) or (i).
